Clinical Trials
38 trialsMulticenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Eastern Cooperative Oncology Group
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Eastern Cooperative Oncology Group
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Masonic Cancer Center, University of Minnesota
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Yale University
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Academic and Community Cancer Research United
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Yale University
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)